GlassScriptPhysician profile
David L Tetrick
NPI 1639183874
$5,960.96
in general payments reported to CMS, 2019-2025
27 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,051 · 2020: $309 · 2022: $560 · 2023: $522 · 2024: $314 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diabetes Care, INC. | $3,780.00 | 2019 | |
| Novo Nordisk INC | $280.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $215.03 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $213.60 | 2020-2025 | Mounjaro, Zepbound |
| Sun Pharmaceutical Industries INC. | $191.28 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $184.52 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $137.80 | 2019-2020 | |
| Glaxosmithkline, LLC. | $116.12 | 2022 | |
| Abbvie INC. | $109.78 | 2022-2025 | Ubrelvy, Vraylar |
| Amgen INC. | $104.33 | 2022-2025 | Evenity, Prolia, Otezla |
| Sunovion Pharmaceuticals INC. | $79.79 | 2019 | |
| Pfizer INC. | $74.94 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $67.57 | 2023-2024 | Nuplazid |
| Astellas Pharma US INC | $60.87 | 2019-2024 | Veozah |
| Neurocrine Biosciences, INC. | $41.48 | 2022-2024 | Ingrezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.64 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.32 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $31.88 | 2019 | |
| Exact Sciences Corporation | $30.98 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $29.85 | 2019-2023 | |
| Lundbeck LLC | $28.96 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.13 | 2022 | |
| Eisai INC. | $21.50 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.38 | 2024 | |
| Mylan Specialty L.P. | $20.25 | 2024 | Yupelri |
| Shire North American Group INC | $14.64 | 2019 | |
| Gilead Sciences, INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tetrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.